The combination of melatonin and sorafenib synergistically suppresses tumor growth in pancreatic cancer xenograft models through the downregulation of the PDGFR-β/STAT3 signaling pathway [39]. This evidence concerns the gene PDGFRB and familial pancreatic carcinoma.